Trellus Health
plc
("Trellus
Health" or the "Company")
Result of
AGM
LONDON, U.K. AND NEW YORK, U.S. (14 June 2024).
Trellus Health plc (AIM: TRLS), a health services
company delivering innovative, scientifically validated programs
and technologies designed to facilitate the management of chronic
conditions, improve health outcomes and lower the costs of care,
announces that at the Annual General
Meeting ("AGM") held earlier today, all resolutions were duly
passed.
The voting results of the AGM were
as follows:
|
|
In Favour
|
Against
|
Withheld
|
|
Resolution
|
Votes
|
At the discretion
of the Chairman
|
%
|
Votes
|
%
|
Votes
|
|
1
|
29,371,910
|
1,563
|
84.23%
|
5,501,588
|
15.77%
|
1,732
|
|
2
|
34,867,051
|
1,563
|
99.99%
|
3,917
|
0.01%
|
4,262
|
|
3
|
34,861,069
|
1,563
|
99.96%
|
12,306
|
0.04%
|
1,855
|
|
4
|
34,831,761
|
1,563
|
99.88%
|
41,614
|
0.12%
|
1,855
|
For
further information please contact:
|
Trellus Health plc
|
https://trellushealth.com/
|
|
Dr. Marla Dubinsky, CEO and
Co-Founder
|
Via Walbrook
PR
|
|
Joy Bessenger, CFO
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser and
Broker)
|
Tel: +44 (0)20 7496
3000
|
|
Aubrey Powell / Jen Boorer / Jalini
Kalaravy
|
|
|
|
|
|
Walbrook PR
|
Tel: +44 (0)20 7933
8780 or trellus@walbrookpr.com
|
|
Paul McManus / Sam Allen / Phillip
Marriage
|
Mob: +44
(0)7980 541 893 / 07748 651 727 / 07867 984
082
|
|
|
| |
About Trellus Health plc (www.trellushealth.com)
Trellus Health (AIM: TRLS) is a
health services company providing value-based innovative solutions
and services for chronic condition management that prioritises
improved outcomes and member experiences while managing costs of
care.
Trellus Health integrates its
proprietary resilience-based methodology with the technology,
tools, and expert coaching and educator team to deliver Trellus
Elevate™, a whole-person technology-enhanced experience that meets
each individual's unique needs and empowers them to master their
physical and emotional health. Trellus Elevate's™ clinically proven
solutions result in relieving disease burden, building
self-management skills and promoting positive health behaviours
that improve outcomes and enables thriving in the face of a chronic
condition.
The Company's proven whole person
approach recognises the interconnectedness of various aspects of a
person's life and aims to address the whole spectrum of factors
that influence behaviour, to promote comprehensive well-being and
human flourishing in a way that aligns with value-based care.
Trellus Health's approach enables better health outcomes in a
member-centric, personalised and comprehensive holistic
solution.
The Company was founded by Mount
Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD,
both experts at treating and healing both the physical and
emotional impacts of IBD and have been innovators for whole-person
healthcare for a combined 50 years.
The Company is initially focusing on
chronic costly GI conditions that have high mental health burden,
such as inflammatory bowel disease ("IBD") which includes the
chronic incurable conditions of Crohn's Disease and ulcerative
colitis. Given the common emotional and mental health struggles
often experienced by individuals suffering from a variety of
chronic conditions, Trellus Health considers its approach to have
potential utility and demand across many conditions.
The Trellus Elevate™ program
incorporates the GRITT™ methodology and learnings on resilience
from clinical research and practice conducted at the Mount Sinai
IBD Center for more than seven years. This proprietary,
resilience-driven methodology has been scientifically validated to
demonstrate meaningful improvements in patient outcomes, 71%
reduction in Emergency Department (A&E) visits, and 94%
reduction in unplanned hospitalisations, which the directors of the
Company believe indicates the potential for significant cost
savings for healthcare payers and health systems. Patients with IBD
managed with the proprietary resilience methodology also
experienced a 49% reduction in required opioid use and a 73%
reduction in corticosteroid use 12 months following starting the
program which is a major indicator of improved health
outcomes1.
Shares in Trellus Health were
admitted to trading on AIM in May 2021, under the ticker TRLS. For
more information on Trellus Health, visit:
www.trellushealth.com
1 Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
